ARO-MAPT / Arrowhead Pharmaceuticals - LARVOL DELTA

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies (Businesswire) - "Our ongoing Phase 1/2 study will evaluate single and multiple doses of ARO-MAPT in healthy volunteers and, in parallel, multiple doses of ARO-MAPT in patients with early Alzheimer’s disease. We anticipate initial data for the first parts of this study will be available in the second half of 2026."

P1/2 data • Trial status • Alzheimer's Disease

Study of ARO-MAPT-SC in Healthy Subjects and Subjects With Early Alzheimer's Disease (clinicaltrials.gov) - P1/2 | N=112 | Recruiting | Sponsor: Arrowhead Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open • Alzheimer's Disease • CNS Disorders

Study of ARO-MAPT-SC in Healthy Subjects and Subjects With Early Alzheimer's Disease (clinicaltrials.gov) - P1/2 | N=112 | Not yet recruiting | Sponsor: Arrowhead Pharmaceuticals

New P1/2 trial • Alzheimer's Disease • CNS Disorders

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies (Arrowhead Press Release) - "Pending clearance, Arrowhead intends to proceed with a Phase 1/2a placebo-controlled dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-MAPT in up to 64 healthy subjects and up to 48 subjects with early Alzheimer’s disease, defined as mild cognitive impairment due to Alzheimer’s disease and mild Alzheimer’s disease dementia."

New P1/2 trial • Alzheimer's Disease • Tauopathies And Synucleinopathies